NCT05233592 is a clinical trial of CGM in Type 1 Diabetes, sponsored by Johns Hopkins University.

Who is sponsoring NCT05233592?

NCT05233592 is sponsored by Johns Hopkins University.

What drugs are being tested in NCT05233592?

Interventions in NCT05233592: CGM.

What condition does NCT05233592 study?

NCT05233592 studies Type 1 Diabetes, Diabetes Mellitus, Type 1.

Is NCT05233592 still recruiting?

NCT05233592 is currently completed. Last updated 17 May 2023.

Last reviewed 2023-05-17 · How we verify

NCT05233592

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Glycemic Effects of the COVID-19 Booster Vaccine in Type 1 Diabetes

Completed Last updated 17 May 2023

What this trial tests

trial testing CGM in Type 1 Diabetes in 21 participants. Completed in 4 April 2023.

Timeline

8 March 2022

Primary endpoint
4 April 2023

4 April 2023

Quick facts

Lead sponsor	Johns Hopkins University
Status	Completed
Study type	OBSERVATIONAL
Enrollment	21
Start date	8 March 2022
Primary completion	4 April 2023
Estimated completion	4 April 2023
Sites	1 location across United States

Drugs / interventions tested

Conditions studied

Type 1 Diabetes — all drugs for Type 1 Diabetes →
Diabetes Mellitus, Type 1 — all drugs for Diabetes Mellitus, Type 1 →

Sponsor

Johns Hopkins University

Who can join

18 and older, any sex, with Type 1 Diabetes or Diabetes Mellitus, Type 1. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Vaccines for COVID-19 are an essential part of combating the coronavirus pandemic. Vaccines "prime" the immune system against an invader (in this case the SARS-CoV-2 virus) by causing a temporary increased immune or inflammatory response. Inflammation can temporarily increase sugar levels and/or insulin requirements among patients with diabetes. The purpose of this study is to investigate whether the "booster" COVID-19 vaccine dose causes temporarily increased sugar levels and/or insulin dose requirements among patients with Type 1 Diabetes (T1D).

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

COVID-19 Vaccines and Hyperglycemia-Is There a Need for Postvaccination Surveillance?
Samuel SM, Varghese E, Triggle CR, Büsselberg D. · · 2022 · cited 20× · PMID 35335086 · DOI 10.3390/vaccines10030454
European Safety Analysis of mRNA and Viral Vector COVID-19 Vaccines on Glucose Metabolism Events.
di Mauro G, Mascolo A, Longo M, Maiorino MI, et al · · 2022 · cited 11× · PMID 35745596 · DOI 10.3390/ph15060677
Transient Hyperglycemia in a Patient With Type 2 Diabetes After COVID-19 Messenger RNA Vaccination: A Case Report.
Okon-Umoren A, Yaphe S, Smith A, Passalacqua KD, et al · · 2024 · PMID 39105031 · DOI 10.7759/cureus.63983

Verify or expand the search:

Other trials of CGM

Trials testing the same drug.

NCT07477249 — Continuous Glucose Monitoring (CGM) in Prediabetes With Community Based Recruitment · NA · recruiting
NCT06863337 — Glucose Pattern in Infertile Women Receiving Assisted Reproduction Using Continuous Glucose Monitoring · NA · recruiting
NCT06883812 — Continuous Glucose Monitoring in Prediabetes With Health Education Videos Among Community Health Workers · NA · completed
NCT06586632 — The Steno Free Trial: AID to Adults with New-onset of Type 1 Diabetes · NA · not yet recruiting
NCT06226948 — Using the Visualization for Lifestyle Change in Patients At Risk of Cardiovascular Diseases · NA · completed

Other recruiting trials for Type 1 Diabetes

Currently open trials in the same condition.

NCT07061574 — A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New On · Phase 1, PHASE2 · recruiting
NCT07360080 — Long-Term Outcomes of Teplizumab in Routine Clinical Care · recruiting
NCT07457580 — Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs) · recruiting
NCT07212179 — Safety and Feasibility of a Self-Learning Bolus Calculator With Simplified Meal Announcement in Adolescents With Type 1 · NA · recruiting
NCT07287943 — To Study the Efficacy and Safety of Medtronic 780G Insulin Pump in People With Gastroparesis and Type 1 Diabetes. · NA · recruiting

Other Johns Hopkins University trials

Trials by the same sponsor.

NCT06236542 — Tracheostomy Robotics and Cutting-edge Health Education for Airway Safety · NA · not yet recruiting
NCT07532252 — Daridorexant for Alcohol Use Disorder · Phase 2 · not yet recruiting
NCT06687655 — Impact of Exogenous Ketones on Sleep Apnea · Phase 1, PHASE2 · not yet recruiting
NCT07079111 — 3D Printed Occlusal Splints for Intraoperative Use · NA · not yet recruiting
NCT02998502 — The Use of a FDA Cleared, Drug-free, Breathing System for Anxiety and Panic Disorders in Children and Teens · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05233592 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Johns Hopkins University
Last refreshed: 17 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05233592.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing